NCT00909129View on ClinicalTrials.gov

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

Not specified

Conditions
Human Immunodeficiency VirusChronic Hepatitis C
Interventions
DRUG

pegylated interferon-alpha (Pegasys)

Pegylated interferon-alpha 2a 180 micrograms s.c. weekly

DRUG

ribavirin (COPEGUS)

ribavirin bid 800-1200 mg depending on HCV genotype and body weight

Trial Locations (1)

SE-171 77

Karolinska University Hospital Solna, Stockholm

All Listed Sponsors
collaborator

The Swedish Research Council

OTHER_GOV

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Karolinska Institutet

OTHER

NCT00909129 - Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment | Biotech Hunter | Biotech Hunter